Shazaad Ahmad
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Interests
Shazaad Ahmad has a total of 225 co-authors. Here are the top co-authors by number of shared publications:
- David T. Arnold
Academic Respiratory Unit, University of Bristol, Bristol, UK
3 shared publications - Emanuela Pelosi
University Hospital Southampton NHS Foundation Trust, Southampton, UK
3 shared publications Felicity Aiano
Immunisation Department, UK Health Security Agency, 61 Colindale Avenue, London, United Kingdom
3 shared publicationsFrances Baawuah
Immunisation Department, UK Health Security Agency, 61 Colindale Avenue, London, United Kingdom
3 shared publications- Jamie Lopez Bernal
UK Health Security Agency, London, UK
3 shared publications Joanne Beckmann
East London NHS Foundation Trust, 9 Allie Street, London, United Kingdom
3 shared publications
Latest Publications
- Open Access
- 3 June 2026
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 81 (7)
A randomized controlled Phase I de-escalation trial of molnupiravir and nirmatrelvir/ritonavir combination for mild-moderate SARS-CoV-2 infection
Objectives: The AGILE CST-8 (NCT04746183) Phase I de-escalation trial evaluated the safety and tolerability of combination molnupiravir and nirmatrelvir/ritonavir for mild-moderate COVID-19. Methods: Adult outpatients with SARS-CoV-2 infection within 5 days of symptoms were randomly assigned 2:1 to receive molnupiravir [starting at 800 mg twice daily (BD) reducing to 600 and 400 mg if necessary] in combination with nirmatrelvir (300 mg)/ritonavir (100 mg) BD for 5 days versus standard of care. Using a dose de-escalation, open-label, Bayesian adaptive Phase I trial, a combination dose was considered unsafe if the probability of 30% or greater dose-limiting toxicity risk (DLT—the primary outcome) over standard of care was 25% or higher. Secondary endpoints included tolerability, clinical progression, pharmacokinetics and virological responses. Results: Of 49 participants screened, 24 were enrolled (16 combination, 8 standard of care) between January 2023 and September 2023. For the primary endpoint, to Day 11, no participant starting molnupiravir at 800 mg BD in combination with nirmatrelvir/ritonavir reported a DLT by Day 11 (primary endpoint) or by Day 29; dose de-escalation was not required. No participants reported severe adverse events (grade ≥3). Although proportions of swab PCR negativity at Day 5 and Day 11 were not statistically different, faster initial viral clearance was observed with treatment. Penetration of nirmatrelvir into saliva, nasal secretions and tears was 19%, 65% and 91% that of plasma. Conclusions: Molnupiravir in combination with nirmatrelvir/ritonavir was safe and well-tolerated; later phase trials should evaluate combination therapy at currently recommended doses for each drug.
- 3 June 2026
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 81 (7)
Open AccessA randomized controlled Phase I de-escalation trial of molnupiravir and nirmatrelvir/ritonavir combination for mild-moderate SARS-CoV-2 infection
Objectives: The AGILE CST-8 (NCT04746183) Phase I de-escalation trial evaluated the safety and tolerability of combination molnupiravir and nirmatrelvir/ritonavir for mild-moderate COVID-19. Methods: Adult outpatients with SARS-CoV-2 infection within 5 days of symptoms were randomly assigned 2:1 to receive molnupiravir [starting at 800 mg twice daily (BD) reducing to 600 and 400 mg if necessary] in combination with nirmatrelvir (300 mg)/ritonavir (100 mg) BD for 5 days versus standard of care. Using a dose de-escalation, open-label, Bayesian adaptive Phase I trial, a combination dose was considered unsafe if the probability of 30% or greater dose-limiting toxicity risk (DLT—the primary outcome) over standard of care was 25% or higher. Secondary endpoints included tolerability, clinical progression, pharmacokinetics and virological responses. Results: Of 49 participants screened, 24 were enrolled (16 combination, 8 standard of care) between January 2023 and September 2023. For the primary endpoint, to Day 11, no participant starting molnupiravir at 800 mg BD in combination with nirmatrelvir/ritonavir reported a DLT by Day 11 (primary endpoint) or by Day 29; dose de-escalation was not required. No participants reported severe adverse events (grade ≥3). Although proportions of swab PCR negativity at Day 5 and Day 11 were not statistically different, faster initial viral clearance was observed with treatment. Penetration of nirmatrelvir into saliva, nasal secretions and tears was 19%, 65% and 91% that of plasma. Conclusions: Molnupiravir in combination with nirmatrelvir/ritonavir was safe and well-tolerated; later phase trials should evaluate combination therapy at currently recommended doses for each drug.
- Open Access
- 6 August 2025
- Published by Elsevier in Journal of Infection
- Vol. 91 (3) , 106570
Burden of respiratory syncytial virus infection in older adults hospitalised in England during 2023/24
- 6 August 2025
- Published by Elsevier in Journal of Infection
- Vol. 91 (3) , 106570
Open AccessBurden of respiratory syncytial virus infection in older adults hospitalised in England during 2023/24
- Open Access
Vaccine effectiveness of a bivalent respiratory syncytial virus (RSV) pre-F vaccine against RSV-associated hospitalisation among adults aged 75-79 years in England
Background: A respiratory syncytial virus (RSV) vaccination programme for older adults using bivalent pre-F vaccine was introduced in England from September 1, 2024. While vaccine effectiveness has been reported against all-cause RSV-associated respiratory hospitalisations, there are limited data on vaccine effectiveness (VE) against different presentations of RSV-associated illness, such as exacerbation of chronic illness. Methods: We conducted a test-negative design analysis using data from a national, hospital-based acute respiratory infection (ARI) sentinel surveillance (HARISS) system across 14 hospitals in England. From October 1, 2024 to March 31, 2025 vaccine-eligible adults aged 75-79 years hospitalised with ARI for ≥24 hours and tested with molecular diagnostic assays within 48 hours of admission were included. Cases were RSV positive, and controls negative for RSV, influenza and SARS-CoV-2. Vaccination status was obtained from the national registry. Findings: Of 1006 adults hospitalised with ARI, 173 (17.2%) had RSV infection. VE was 82.3% (95%CI:70.6-90.0%) against hospitalisation for any RSV-associated ARI and 86.7% (75.4-93.6%) in those with severe disease including oxygen supplementation. VE was 88.6% (75.6-95.6%) among adults admitted due to lower respiratory tract infection (LRTI), including pneumonia, 77.4% (42.4-92.8%) among adults admitted due to exacerbation of chronic lung disease, and 78.8% (47.8-93.0%) among adults admitted with exacerbation of chronic heart disease, lung disease or frailty. In adults with immunosuppression, VE was 72.8% (39.5-89.3%). Interpretation: This study provides evidence that the RSV pre-F vaccine is highly effective against RSV-associated hospitalisations, including exacerbations of chronic disease and in adults living with immunosuppression. Funding: The UK Health Security Agency.
Open AccessVaccine effectiveness of a bivalent respiratory syncytial virus (RSV) pre-F vaccine against RSV-associated hospitalisation among adults aged 75-79 years in England
Background: A respiratory syncytial virus (RSV) vaccination programme for older adults using bivalent pre-F vaccine was introduced in England from September 1, 2024. While vaccine effectiveness has been reported against all-cause RSV-associated respiratory hospitalisations, there are limited data on vaccine effectiveness (VE) against different presentations of RSV-associated illness, such as exacerbation of chronic illness. Methods: We conducted a test-negative design analysis using data from a national, hospital-based acute respiratory infection (ARI) sentinel surveillance (HARISS) system across 14 hospitals in England. From October 1, 2024 to March 31, 2025 vaccine-eligible adults aged 75-79 years hospitalised with ARI for ≥24 hours and tested with molecular diagnostic assays within 48 hours of admission were included. Cases were RSV positive, and controls negative for RSV, influenza and SARS-CoV-2. Vaccination status was obtained from the national registry. Findings: Of 1006 adults hospitalised with ARI, 173 (17.2%) had RSV infection. VE was 82.3% (95%CI:70.6-90.0%) against hospitalisation for any RSV-associated ARI and 86.7% (75.4-93.6%) in those with severe disease including oxygen supplementation. VE was 88.6% (75.6-95.6%) among adults admitted due to lower respiratory tract infection (LRTI), including pneumonia, 77.4% (42.4-92.8%) among adults admitted due to exacerbation of chronic lung disease, and 78.8% (47.8-93.0%) among adults admitted with exacerbation of chronic heart disease, lung disease or frailty. In adults with immunosuppression, VE was 72.8% (39.5-89.3%). Interpretation: This study provides evidence that the RSV pre-F vaccine is highly effective against RSV-associated hospitalisations, including exacerbations of chronic disease and in adults living with immunosuppression. Funding: The UK Health Security Agency.
- Open Access
A randomised-controlled Phase I de-escalation trial of Molnupiravir and Nirmatrelvir/Ritonavir combination for mild-moderate SARS-CoV-2 infection
Summary: Background: The AGILE CST-8 ( NCT04746183 ) Phase I de-escalation trial evaluated the safety and tolerability of combination molnupiravir and nirmatrelvir/ritonavir for mild-moderate COVID-19. Methods: Adult out-patients with SARS-CoV-2 infection within five days of symptoms were randomly assigned 2:1 to receive molnupiravir (starting at 800mg twice daily (BD) reducing to 600mg and 400mg if necessary) in combination with nirmatrelvir (300mg)/ritonavir (100mg) BD for 5 days versus Standard of care. Using a dose de-escalation, open-label, Bayesian adaptive Phase I trial a combination dose was considered unsafe if the probability of 30% or greater dose-limiting toxicity risk (DLT - the primary outcome) over standard of care was 25% or higher. Secondary endpoints included tolerability, clinical progression, pharmacokinetics and virological responses. Findings: Of 49 participants screened, 24 were enrolled (16 combination, 8 standard of care) between January 2023 and September 2023. For the primary endpoint, to day 11, no participant starting molnupiravir at 800mg (BD) in combination with nirmatrelvir/ritonavir reported a DLT by day 11 (primary endpoint) or by day 29; dose de-escalation was not required. No participants reported severe adverse events (grade>=3). Although proportion of swab PCR negativity at day 5 and day 11 were not statistically different, faster initial viral clearance was observed with treatment. Penetration of nirmatrelvir into saliva, nasal secretions and tears was 19%, 65% and 91% that of plasma. Interpretation: Molnupiravir in combination with nirmatrelvir/ritonavir was safe and well-tolerated; later phase trials should evaluate combination therapy at currently recommended doses for each drug. Research in Context: Evidence before this study: SARS-CoV-2 antivirals such as nirmatrelvir/ritonavir, remdesivir and molnupiravir have been associated with clinical benefit and faster viral clearance when given early to patients at high-risk of severe disease. However, evidence has accrued to suggest that virus persists in tissues (e.g. gastrointestinal tract) and in blood even after clearance from the upper respiratory tract. Moreover, persistent viral infection is recognised in individuals who are the most severely immunosuppressed, (e.g. transplant recipients, those with haematological malignancy, or receiving B-cell depleting therapies) suggesting greater antiviral potency is needed. A PubMed search (26 th April 2025) using the terms ‘SARS-CoV-2’ AND ‘antiviral’ AND ‘combination therapy’ revealed descriptions of retrospective and prospective of case series of combination antiviral therapy, usually given to severely immunocompromised patients. Once prospective study from Naples evaluated the monoclonal antibody sotrovimab in combination with antiviral small molecules, without any controls. There were no randomised trials of combination antiviral therapy for SARS-CoV-2, and little recognition that use of agents at their licensed doses might not be be equally safe when combined. Added value of this study: Coadministration of molnupiravir and nirmatrelvir/ritonavir (at fully licensed doses) is safe and well-tolerated. Although numbers were small and no differences were detectable in time to achieving PCR-negative swabs, we observed a significantly faster rate of initial viral clearance with combination therapy (compared with no antiviral therapy) using a biexponential model to examine the initial ‘fast’ decay in viral elimination. Implications of all the available evidence: Molnupiravir plus nirmatrelvir/ritonavir represents an oral-based combination regimen for SARS-CoV-2 infection which should be evaluated against conventional monotherapy, particularly in patients with severe immunosuppression. The use of an adaptive Bayesian dose de-escalation design offers advantages in statistical precision and efficient decision-making for combination antiviral therapy.
Open AccessA randomised-controlled Phase I de-escalation trial of Molnupiravir and Nirmatrelvir/Ritonavir combination for mild-moderate SARS-CoV-2 infection
Summary: Background: The AGILE CST-8 ( NCT04746183 ) Phase I de-escalation trial evaluated the safety and tolerability of combination molnupiravir and nirmatrelvir/ritonavir for mild-moderate COVID-19. Methods: Adult out-patients with SARS-CoV-2 infection within five days of symptoms were randomly assigned 2:1 to receive molnupiravir (starting at 800mg twice daily (BD) reducing to 600mg and 400mg if necessary) in combination with nirmatrelvir (300mg)/ritonavir (100mg) BD for 5 days versus Standard of care. Using a dose de-escalation, open-label, Bayesian adaptive Phase I trial a combination dose was considered unsafe if the probability of 30% or greater dose-limiting toxicity risk (DLT - the primary outcome) over standard of care was 25% or higher. Secondary endpoints included tolerability, clinical progression, pharmacokinetics and virological responses. Findings: Of 49 participants screened, 24 were enrolled (16 combination, 8 standard of care) between January 2023 and September 2023. For the primary endpoint, to day 11, no participant starting molnupiravir at 800mg (BD) in combination with nirmatrelvir/ritonavir reported a DLT by day 11 (primary endpoint) or by day 29; dose de-escalation was not required. No participants reported severe adverse events (grade>=3). Although proportion of swab PCR negativity at day 5 and day 11 were not statistically different, faster initial viral clearance was observed with treatment. Penetration of nirmatrelvir into saliva, nasal secretions and tears was 19%, 65% and 91% that of plasma. Interpretation: Molnupiravir in combination with nirmatrelvir/ritonavir was safe and well-tolerated; later phase trials should evaluate combination therapy at currently recommended doses for each drug. Research in Context: Evidence before this study: SARS-CoV-2 antivirals such as nirmatrelvir/ritonavir, remdesivir and molnupiravir have been associated with clinical benefit and faster viral clearance when given early to patients at high-risk of severe disease. However, evidence has accrued to suggest that virus persists in tissues (e.g. gastrointestinal tract) and in blood even after clearance from the upper respiratory tract. Moreover, persistent viral infection is recognised in individuals who are the most severely immunosuppressed, (e.g. transplant recipients, those with haematological malignancy, or receiving B-cell depleting therapies) suggesting greater antiviral potency is needed. A PubMed search (26 th April 2025) using the terms ‘SARS-CoV-2’ AND ‘antiviral’ AND ‘combination therapy’ revealed descriptions of retrospective and prospective of case series of combination antiviral therapy, usually given to severely immunocompromised patients. Once prospective study from Naples evaluated the monoclonal antibody sotrovimab in combination with antiviral small molecules, without any controls. There were no randomised trials of combination antiviral therapy for SARS-CoV-2, and little recognition that use of agents at their licensed doses might not be be equally safe when combined. Added value of this study: Coadministration of molnupiravir and nirmatrelvir/ritonavir (at fully licensed doses) is safe and well-tolerated. Although numbers were small and no differences were detectable in time to achieving PCR-negative swabs, we observed a significantly faster rate of initial viral clearance with combination therapy (compared with no antiviral therapy) using a biexponential model to examine the initial ‘fast’ decay in viral elimination. Implications of all the available evidence: Molnupiravir plus nirmatrelvir/ritonavir represents an oral-based combination regimen for SARS-CoV-2 infection which should be evaluated against conventional monotherapy, particularly in patients with severe immunosuppression. The use of an adaptive Bayesian dose de-escalation design offers advantages in statistical precision and efficient decision-making for combination antiviral therapy.
- Open Access
Estimating the disease burden of respiratory syncytial virus (RSV) in older adults in England during the 2023/24 season: a new national hospital-based surveillance system
Background Respiratory syncytial virus (RSV) is an important cause of acute respiratory infection (ARI) in older adults. Vaccines that protect against severe RSV infection are now available. Aim We aimed to describe the incidence, presentation, severity and clinical outcomes of RSV-associated ARI in hospitalised older adults using a new Hospital-based ARI Sentinel Surveillance (HARISS) system in England in the winter prior to RSV vaccine introduction. Methods Adults aged ≥65 years from seven hospitals admitted for ≥24 hours with symptomatic ARI were included. Three groups were identified: RSV positive; influenza positive; negative for RSV, influenza and SARS-CoV-2. We estimated the hospitalisation rate of RSV-associated ARI compared to influenza-associated ARI and assessed clinical outcomes using Poisson regression and mortality using Cox regression across groups. Results This surveillance study included 2743 adults. During the 2023/4 season the hospitalisation rate for RSV-associated ARI was 58.3 per 100,000, compared to 114.6 per 100,000 for influenza-associated ARI. Hospitalisation rates increased with age. Exacerbation of chronic illness including lung disease, heart disease or frailty was a frequent cause of admission in RSV-associated ARI, with a combined incidence of 33.1 per 100,000. The majority of adults with RSV-associated ARI had at least one comorbidity (81%); a high proportion with immunosuppression (26%). Symptoms and clinical outcomes including mortality were similar between RSV- and influenza-associated ARI; 30-day mortality 10.6% vs 8.7% (adjusted hazard ratio 0.85,95% confidence interval 0.6-1.2). Conclusion In England, RSV infection is a common cause of hospitalisation in older adults. Symptoms at presentation, severity and clinical outcomes, including mortality, are comparable to influenza.
Open AccessEstimating the disease burden of respiratory syncytial virus (RSV) in older adults in England during the 2023/24 season: a new national hospital-based surveillance system
Background Respiratory syncytial virus (RSV) is an important cause of acute respiratory infection (ARI) in older adults. Vaccines that protect against severe RSV infection are now available. Aim We aimed to describe the incidence, presentation, severity and clinical outcomes of RSV-associated ARI in hospitalised older adults using a new Hospital-based ARI Sentinel Surveillance (HARISS) system in England in the winter prior to RSV vaccine introduction. Methods Adults aged ≥65 years from seven hospitals admitted for ≥24 hours with symptomatic ARI were included. Three groups were identified: RSV positive; influenza positive; negative for RSV, influenza and SARS-CoV-2. We estimated the hospitalisation rate of RSV-associated ARI compared to influenza-associated ARI and assessed clinical outcomes using Poisson regression and mortality using Cox regression across groups. Results This surveillance study included 2743 adults. During the 2023/4 season the hospitalisation rate for RSV-associated ARI was 58.3 per 100,000, compared to 114.6 per 100,000 for influenza-associated ARI. Hospitalisation rates increased with age. Exacerbation of chronic illness including lung disease, heart disease or frailty was a frequent cause of admission in RSV-associated ARI, with a combined incidence of 33.1 per 100,000. The majority of adults with RSV-associated ARI had at least one comorbidity (81%); a high proportion with immunosuppression (26%). Symptoms and clinical outcomes including mortality were similar between RSV- and influenza-associated ARI; 30-day mortality 10.6% vs 8.7% (adjusted hazard ratio 0.85,95% confidence interval 0.6-1.2). Conclusion In England, RSV infection is a common cause of hospitalisation in older adults. Symptoms at presentation, severity and clinical outcomes, including mortality, are comparable to influenza.
- Open Access
- 3 November 2023
- Published by Elsevier in Respiratory Medicine and Research
- Vol. 84, 101061
The benefits of COVID lockdowns on respiratory health: What factors may have contributed to the decline in hospital admissions for cystic fibrosis?
- 3 November 2023
- Published by Elsevier in Respiratory Medicine and Research
- Vol. 84, 101061
Open AccessThe benefits of COVID lockdowns on respiratory health: What factors may have contributed to the decline in hospital admissions for cystic fibrosis?
- Open Access
- 3 September 2023
- Published by Elsevier in Journal of Infection
- Vol. 87 (5) , 403-412
Nasal mucosal IgA levels against SARS-CoV-2 and seasonal coronaviruses are low in children but boosted by reinfection
- 3 September 2023
- Published by Elsevier in Journal of Infection
- Vol. 87 (5) , 403-412
Open AccessNasal mucosal IgA levels against SARS-CoV-2 and seasonal coronaviruses are low in children but boosted by reinfection
- Open Access
Parents’ and teachers’ attitudes to and experiences of the implementation of COVID-19 preventive measures in primary and secondary schools following reopening of schools in autumn 2020: a descriptive cross-sectional survey
Objective To assess implementation and ease of implementation of control measures in schools as reported by staff and parents. Design A descriptive cross-sectional survey. Setting Staff and parents/guardians of the 132 primary schools and 19 secondary schools participating in COVID-19 surveillance in school kids (sKIDs and sKIDsPLUS Studies). Main outcome measure Prevalence of control measures implemented in schools in autumn 2020, parental and staff perception of ease of implementation. Results In total, 56 of 151 (37%) schools participated in this study, with 1953 parents and 986 staff members completing the questionnaire. Most common measures implemented by schools included regular hand cleaning for students (52 of 56, 93%) and staff (70 of 73, 96%), as reported by parents and staff, respectively, and was among the easiest to implement at all times for students (57%) and even more so, for staff (78%). Maintaining 2-metre distancing was less commonly reported for students (24%–51%) as it was for staff (81%–84%), but was one of the most difficult to follow at all times for students (25%) and staff (16%) alike. Some measures were more commonly reported by primary school compared to secondary school parents, including keeping students within the same small groups (28 of 41, 68% vs 8 of 15, 53%), ensuring the same teacher for classes (29 of 41, 71% vs 6 of 15, 40%). On the other hand, wearing a face covering while at school was reported by three-quarters of secondary school parents compared with only parents of 4 of 41 (10%) primary schools. Other measures such as student temperature checks (5%–13%) and advising staff work from home if otherwise healthy (7%–15%) were rarely reported. Conclusions Variable implementation of infection control measures was reported, with some easier to implement (hand hygiene) than others (physical distancing).
Open AccessParents’ and teachers’ attitudes to and experiences of the implementation of COVID-19 preventive measures in primary and secondary schools following reopening of schools in autumn 2020: a descriptive cross-sectional survey
Objective To assess implementation and ease of implementation of control measures in schools as reported by staff and parents. Design A descriptive cross-sectional survey. Setting Staff and parents/guardians of the 132 primary schools and 19 secondary schools participating in COVID-19 surveillance in school kids (sKIDs and sKIDsPLUS Studies). Main outcome measure Prevalence of control measures implemented in schools in autumn 2020, parental and staff perception of ease of implementation. Results In total, 56 of 151 (37%) schools participated in this study, with 1953 parents and 986 staff members completing the questionnaire. Most common measures implemented by schools included regular hand cleaning for students (52 of 56, 93%) and staff (70 of 73, 96%), as reported by parents and staff, respectively, and was among the easiest to implement at all times for students (57%) and even more so, for staff (78%). Maintaining 2-metre distancing was less commonly reported for students (24%–51%) as it was for staff (81%–84%), but was one of the most difficult to follow at all times for students (25%) and staff (16%) alike. Some measures were more commonly reported by primary school compared to secondary school parents, including keeping students within the same small groups (28 of 41, 68% vs 8 of 15, 53%), ensuring the same teacher for classes (29 of 41, 71% vs 6 of 15, 40%). On the other hand, wearing a face covering while at school was reported by three-quarters of secondary school parents compared with only parents of 4 of 41 (10%) primary schools. Other measures such as student temperature checks (5%–13%) and advising staff work from home if otherwise healthy (7%–15%) were rarely reported. Conclusions Variable implementation of infection control measures was reported, with some easier to implement (hand hygiene) than others (physical distancing).
- 1 November 2021
- Published by Elsevier in Journal of Infection
- Vol. 83 (5) , 573-580
Emergence of SARS-CoV-2 Alpha (B.1.1.7) variant, infection rates, antibody seroconversion and seroprevalence rates in secondary school students and staff: Active prospective surveillance, December 2020 to March 2021, England
- 1 November 2021
- Published by Elsevier in Journal of Infection
- Vol. 83 (5) , 573-580
Emergence of SARS-CoV-2 Alpha (B.1.1.7) variant, infection rates, antibody seroconversion and seroprevalence rates in secondary school students and staff: Active prospective surveillance, December 2020 to March 2021, England
- Open Access
Characterising post-COVID syndrome more than 6 months after acute infection in adults; prospective longitudinal cohort study, England
Background Most individuals with COVID-19 will recover without sequelae, but some will develop long-term multi-system impairments. The definition, duration, prevalence and symptoms associated with long COVID, however, have not been established. Methods Public Health England (PHE) initiated longitudinal surveillance of clinical and non-clinical healthcare workers for monthly assessment and blood sampling for SARS-CoV-2 antibodies in March 2020. Eight months after enrolment, participants completed an online questionnaire including 72 symptoms in the preceding month. Symptomatic mild-to-moderate cases with confirmed COVID-19 were compared with asymptomatic, seronegative controls. Multivariable logistic regression was used to identify independent symptoms associated with long COVID. Findings All 2,147 participants were contacted and 1,671 (77.8%) completed the questionnaire, including 140 (8.4%) cases and 1,160 controls. At a median of 7.5 (IQR 7.1-7.8) months after infection, 20 cases (14.3%) had ongoing (4/140, 2.9%) or episodic (16/140, 11.4%) symptoms. We identified three clusters of symptoms associated with long COVID, those affecting the sensory (ageusia, anosmia, loss of appetite and blurred vision), neurological (forgetfulness, short-term memory loss and confusion/brain fog) and cardiorespiratory (chest tightness/pain, unusual fatigue, breathlessness after minimal exertion/at rest, palpitations) systems. The sensory cluster had the highest association with being a case (aOR 5.25, 95% CI 3.45-8.01). Dermatological, gynaecological, gastrointestinal or mental health symptoms were not significantly different between cases and controls. Interpretation Most persistent symptoms reported following mild COVID-19 were equally common in cases and controls. While all three clusters identified had a strong association with cases, the sensory cluster had the highest specificity and strength of association, and therefore, most likely to be characteristic of long COVID. Funding PHE. Evidence before this study We searched PubMed using search terms “long covid*” OR “post COVID*” in adults for studies including cohort, case reports, randomised control trials, cross-sectional and systematic reviews published up to 12 March 2020 without any language restrictions. Most reports included a small number of cases. Larger studies included very specific cohorts, including hospitalised cases and self-selected participants with COVID-19. A systematic review identified 15 studies and, using a broad case definition, concluded that 80% (95% CI 65-92) of patients with SARS-CoV-2 developed one or more long-term symptoms. The five most common symptoms were fatigue (58%), headache (44%), attention disorder (27%), hair loss (25%), and dyspnea (24%), but no assessment was made of these symptoms in uninfected adults. Added value of this study In a prospective, longitudinal cohort of clinical and non-clinical healthcare workers recruited at the start of the pandemic, we found that most self-reported symptoms were as common in 140 adults who developed mild-to-moderate COVID-19 more than 6 months previously compared to 1,160 controls who were asymptomatic and SARS-CoV-2 antibody negative throughout the surveillance period. Compared to controls, we identified three clusters of symptoms affecting the sensory, neurological and cardiorespiratory systems that were more prevalent among cases. Notably, symptoms affecting other organ systems were as prevalent among cases as controls. The high proportion of cases and controls reporting mental health symptoms highlights the toll that the pandemic has had on healthcare workers Implications of all the available evidence Our findings highlight the importance of including a representative cohort of cases to assess long-term outcomes of COVID-19 as well as appropriate controls to estimate the relative prevalence of self-reported symptoms to accurately define this new syndrome. Our study adds to the evidence-base for long COVID in adults with mild-to-moderate COVID-19 who contribute to the vast majority of 120+ million infections worldwide. This information is not only important for clinicians, patients and the public, but also for policy makers and healthcare providers who are investing heavily in long-term provisions for COVID-19 survivors.
Open AccessCharacterising post-COVID syndrome more than 6 months after acute infection in adults; prospective longitudinal cohort study, England
Background Most individuals with COVID-19 will recover without sequelae, but some will develop long-term multi-system impairments. The definition, duration, prevalence and symptoms associated with long COVID, however, have not been established. Methods Public Health England (PHE) initiated longitudinal surveillance of clinical and non-clinical healthcare workers for monthly assessment and blood sampling for SARS-CoV-2 antibodies in March 2020. Eight months after enrolment, participants completed an online questionnaire including 72 symptoms in the preceding month. Symptomatic mild-to-moderate cases with confirmed COVID-19 were compared with asymptomatic, seronegative controls. Multivariable logistic regression was used to identify independent symptoms associated with long COVID. Findings All 2,147 participants were contacted and 1,671 (77.8%) completed the questionnaire, including 140 (8.4%) cases and 1,160 controls. At a median of 7.5 (IQR 7.1-7.8) months after infection, 20 cases (14.3%) had ongoing (4/140, 2.9%) or episodic (16/140, 11.4%) symptoms. We identified three clusters of symptoms associated with long COVID, those affecting the sensory (ageusia, anosmia, loss of appetite and blurred vision), neurological (forgetfulness, short-term memory loss and confusion/brain fog) and cardiorespiratory (chest tightness/pain, unusual fatigue, breathlessness after minimal exertion/at rest, palpitations) systems. The sensory cluster had the highest association with being a case (aOR 5.25, 95% CI 3.45-8.01). Dermatological, gynaecological, gastrointestinal or mental health symptoms were not significantly different between cases and controls. Interpretation Most persistent symptoms reported following mild COVID-19 were equally common in cases and controls. While all three clusters identified had a strong association with cases, the sensory cluster had the highest specificity and strength of association, and therefore, most likely to be characteristic of long COVID. Funding PHE. Evidence before this study We searched PubMed using search terms “long covid*” OR “post COVID*” in adults for studies including cohort, case reports, randomised control trials, cross-sectional and systematic reviews published up to 12 March 2020 without any language restrictions. Most reports included a small number of cases. Larger studies included very specific cohorts, including hospitalised cases and self-selected participants with COVID-19. A systematic review identified 15 studies and, using a broad case definition, concluded that 80% (95% CI 65-92) of patients with SARS-CoV-2 developed one or more long-term symptoms. The five most common symptoms were fatigue (58%), headache (44%), attention disorder (27%), hair loss (25%), and dyspnea (24%), but no assessment was made of these symptoms in uninfected adults. Added value of this study In a prospective, longitudinal cohort of clinical and non-clinical healthcare workers recruited at the start of the pandemic, we found that most self-reported symptoms were as common in 140 adults who developed mild-to-moderate COVID-19 more than 6 months previously compared to 1,160 controls who were asymptomatic and SARS-CoV-2 antibody negative throughout the surveillance period. Compared to controls, we identified three clusters of symptoms affecting the sensory, neurological and cardiorespiratory systems that were more prevalent among cases. Notably, symptoms affecting other organ systems were as prevalent among cases as controls. The high proportion of cases and controls reporting mental health symptoms highlights the toll that the pandemic has had on healthcare workers Implications of all the available evidence Our findings highlight the importance of including a representative cohort of cases to assess long-term outcomes of COVID-19 as well as appropriate controls to estimate the relative prevalence of self-reported symptoms to accurately define this new syndrome. Our study adds to the evidence-base for long COVID in adults with mild-to-moderate COVID-19 who contribute to the vast majority of 120+ million infections worldwide. This information is not only important for clinicians, patients and the public, but also for policy makers and healthcare providers who are investing heavily in long-term provisions for COVID-19 survivors.